CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Response by Kaier et al to Letter Regarding Article, “Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction” The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE) Prospective Study of Percutaneous Coronary Intervention: Study Design Subclinical Atherosclerosis Burden by 3D Ultrasound in Mid-Life: The PESA Study Letter by Jiang et al Regarding Article, “Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction” Biological Versus Chronological Aging: JACC Focus Seminar Clinical Implications of Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion: Role of Antegrade and Retrograde Crossing Techniques Mechanisms of Vascular Aging, A Geroscience Perspective JACC Focus Seminar Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease ACC临床简报:新型冠状病毒对心脏的影响(2019-nCoV) Age-specific gender differences in early mortality following ST-segment elevation myocardial infarction in China
|<<... 13 14 15 16 17 18 19 ...>>|

Guideline2019 Jan 28. pii: S1547-5271(19)30037-2.

JOURNAL：Heart Rhythm. Article Link

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

January CT, Wann LS, Calkins H et al. Keywords: acute coronary syndrome; anticoagulants; antiplatelet agents; apixaban; atrial fibrillation; atrial flutter; coronary artery disease; dabigatran; edoxaban; idarucizumab; warfarin;

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top